1,721,044 research outputs found
Transplantation for liver tumors: current status
No full textThe question of liver transplantation for hepatobiliary malignancy has continued to generate controversial discussion. As shown by single-center studies and large databases, there is a clear indication for total hepatectomy and liver replacement under the premises of appropriate selection of suitable patients as well as of favorable type and stage of tumors. Future improvement of tumor-free patient survival can be expected from better understanding of tumor biology, including prevention and earlier detection of cancer, and effective multimodality treatment strategies
Liver regeneration is different in living donors and recipients following hepatic transplantation.
No full textLiver regeneration is different in living donors and recipients following hepatic transplantation.
No full textInterferon alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation
No full textCharacterization and influence of risk factors on initial liver function after transplantation
No full textReplacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression
No full textPantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients
No full textObjective: Renal-transplant patients who are immunosuppressed with cyclosporin A (CyA) are often treated with proton-pump inhibitors to prevent ulcer disease. No data are available on the effect of the novel proton-pump inhibitor pantoprazole on CyA levels. Methods: In a controlled treatment, we investigated the effect of pantoprazole, which was administered in a pragmatic schedule for acid suppression (40 mg as single oral dose at 2200 hours) in six renal-transplant patients who received CyA (Sandimmun optoral, 50-175 mg twice daily) and prednisolone (5-7.5 mg/24 h). CS/A trough levels (0730-0800 hours) were measured by immunoassay. Results: In the absence of pantoprazole, mean CyA trough levels measured on three consecutive days were the avaletween 164 ng/ml and 173 ng/ml (therapeutic range pump inhibitors 120-200 ng/ml). Pantoprazole did not affect CyA trough levels during an observation period up to 3 months long. Conclusions: Pantoprazole seems to be a safe drug in combination with CyA
The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients
No full text- …
